Last reviewed · How we verify

NCT03346889: VOVS

Vestibular Outcomes in Vestibular Schwannoma

Active, enrolled Last updated 30 October 2024
What this trial tests

trial in Vestibular Schwannoma in 155 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
23 April 2017
Primary endpoint
25 June 2019
31 December 2025

Quick facts

Lead sponsorHaukeland University Hospital
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment155
Start date23 April 2017
Primary completion25 June 2019
Estimated completion31 December 2025
Sites1 location across Norway

Conditions studied

Sponsor

Haukeland University Hospital

Who can join

Eligibility, any sex, with Vestibular Schwannoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Previous studies have shown that vertigo is the symptoms that mostly affect quality of life in patients with vestibular schwannoma. There is still limited knowledge as to why some patients with this disorder develop vertigo, while others with the same diagnosis do not. The purpose of this study is to measure symptom-related quality of life and to relate this to objective disease characteristics at baseline.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Vestibular Schwannoma

Currently open trials in the same condition.

Other Haukeland University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03346889.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing